Alkermes narcolepsy drug meets phase 2 trial endpoints

June 17, 2026 4:15 PM

Alkermes plc (NASDAQ: ALKS) presented detailed results from its Vibrance-2 phase 2 study of alixorexton in adults with narcolepsy type ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found